# A Study of OPC-262 in Patients With Type 2 Diabetes

> **NCT00997282** · PHASE2,PHASE3 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 255 (estimated)

## Conditions studied

- Diabetes Type 2

## Interventions

- **DRUG:** OPC-262 2.5 mg
- **DRUG:** OPC-262 5 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00997282
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2014-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00997282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00997282, "A Study of OPC-262 in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00997282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*